This HTML5 document contains 147 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q43950860
rdf:type
wikibase:Item
schema:description
2013年学术文章 2013年學術文章 articol științific artículo científico publicado en 2013 teaduslik artikkel scienca artikolo επιστημονικό άρθρο 2013年学术文章 artikulong pang-agham vědecký článek tieteellinen artikkeli ২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2013年學術文章 bilimsel makale article científic мақолаи илмӣ სამეცნიერო სტატია 2013年学术文章 2013年学术文章 vitskapeleg artikkel 2013年學術文章 naučni članak مقالهٔ علمی מאמר מדעי 2013 nî lūn-bûn mokslinis straipsnis artigo científico (publicado na 2013) سائنسی مضمون мақолаи илмӣ научна статия article scientific vedecký článok article scientifique (publié 2013) tudományos cikk artículu científicu espublizáu en 2013 2013年の論文 artigo científico vitenskapelig artikkel научни чланак 2013年學術文章 articolo scientifico научни чланак 2013년 논문 wetenschappelijk artikel 2013年学术文章 artikull shkencor artykuł naukowy 2013年學術文章 wissenschaftlicher Artikel գիտական հոդված مقالة علمية vetenskaplig artikel 2013年學術文章 наукова стаття, опублікована в жовтні 2013 artigo científico (publicado na 2013) บทความทางวิทยาศาสตร์ научная статья videnskabelig artikel (udgivet 2013) bài báo khoa học scientific article
p:P577
wds:Q43950860-4B051E15-4FFC-489A-A134-3A714C135F80
wdt:P577
2013-10-29T00:00:00Z
p:P407
wds:Q43950860-EE3CDD2A-4C46-4519-A11A-D92152E1BE9A
wdt:P407
wd:Q1860
p:P2860
wds:Q43950860-33BB7F5C-9F83-4218-8519-EEC87E989975 wds:Q43950860-44A2DAAC-DB00-4565-B097-93AD9CBAB51F wds:Q43950860-455EEF8F-0E44-4D99-8274-E0C9A3CDBB4B wds:Q43950860-A1C4DA87-996C-4046-BE4A-363E9870000B wds:Q43950860-77C1CF8F-B2C7-4BC1-A2BC-1F2FFEE21DD1 wds:Q43950860-89C601E5-4A99-4BF3-B61D-4CEDCE08574F wds:Q43950860-8BFA52A7-437F-4301-A3DD-DE31B73EA6EE wds:Q43950860-04B8318D-B853-4E10-9713-9ECE521E48F0 wds:Q43950860-0C8D50C3-37A1-42FB-8A2D-3D0010A57BD6 wds:Q43950860-1D70886A-5BC7-42E0-A7AE-9139BDD99A7C wds:Q43950860-11254AF4-1168-444D-89C0-3F05BB2D0276 wds:Q43950860-E0B93FE8-A83C-486F-BF2E-26B9E27389FA wds:Q43950860-F2279DD4-2CA1-40D9-8DE8-BFF410E12BD4 wds:Q43950860-D0895F2B-1FD6-4B5D-A6BB-816DA72BB76A wds:Q43950860-D97CBFAA-116C-4EBC-88A2-362027E98E87 wds:Q43950860-FCC0A5AD-A303-43D3-AB09-B8D2B88A8DCD wds:Q43950860-F7C43C6A-8133-4CAA-AA26-E3088F7B7C63 wds:Q43950860-F87EDB7F-1D09-4D11-8DD7-AC096A0F06C4
wdt:P2860
wd:Q29616359 wd:Q53097045 wd:Q27861075 wd:Q27860530 wd:Q53147159 wd:Q27025724 wd:Q37162908 wd:Q27860783 wd:Q85009916 wd:Q29547903 wd:Q37696396 wd:Q29616230 wd:Q44365458 wd:Q37003248 wd:Q50522011 wd:Q35584820 wd:Q28131668 wd:Q37701152
rdfs:label
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design
skos:prefLabel
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design
schema:name
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design
p:P50
wds:Q43950860-15037E52-7FA4-4A88-829E-C322F1A6FE23 wds:Q43950860-195BBE40-BA9A-4E85-9D45-F412E6CF955A wds:Q43950860-1AFCF822-A0C0-4100-B740-EB0289E5AC65 wds:Q43950860-2058C6B4-0079-4662-B572-1B024E4C901C wds:Q43950860-A054C295-E612-4421-B7BD-D83A38878DAF wds:Q43950860-4D1610D7-0F08-479C-9724-44DE03C8EFC2 wds:Q43950860-7556C891-D3DA-442C-B0A5-1C55F576DD45 wds:Q43950860-D72B3947-069C-4075-AF48-FB6109E79A3E wds:Q43950860-DC96F3C2-263B-4C0E-8910-1A875BA3DE0F wds:Q43950860-F159AFC9-A17A-449E-A456-42AA0624EBF4
wdt:P50
wd:Q37393088 wd:Q41554561 wd:Q37393143 wd:Q91939991 wd:Q43117839 wd:Q56592266 wd:Q91459537 wd:Q64148536 wd:Q54267038 wd:Q43088594
p:P1476
wds:Q43950860-F2F8D63B-4068-45D0-9C68-14CC4EB89998
wdt:P1476
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design
p:P304
wds:Q43950860-2F9F8962-134B-4665-AF76-750B7B032FC1
wdt:P304
2023-2031
p:P31
wds:Q43950860-A3C30E7E-604E-413F-B57D-2CA8D24A06F4
wdt:P31
wd:Q13442814
p:P921
wds:Q43950860-74904E7C-472C-4FA1-B94B-9BA12EE8D19C
wdt:P921
wd:Q1148337
p:P698
wds:Q43950860-1556DC2F-8F81-402A-BA9D-7E7035558CE2
wdtn:P698
n8:23787822
wdt:P698
23787822
p:P1433
wds:Q43950860-61E751B1-4D1A-4911-97A8-4D56C92D6A35
wdt:P1433
wd:Q15724398
p:P433
wds:Q43950860-85706B24-C15C-463E-A79E-7864BB56D5CC
p:P478
wds:Q43950860-FBB8F346-95AB-4F61-8DEA-271BBE9351C4
wdt:P433
6
wdt:P478
58
p:P356
wds:Q43950860-AD84A3A6-1716-4ABE-957E-8D437BC5D95B
wdtn:P356
n12:HEP.26586
wdt:P356
10.1002/HEP.26586